Neumora Therapeutics, Inc. Common StockNMRANASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+26.7%
5Y CAGR+49.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+26.7%/yr
Annual compound
5Y CAGR
+49.8%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
7.5x
Strong expansion
Streak
5 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$63.29M+1.2%
2024$62.54M+39.6%
2023$44.81M+44.0%
2022$31.12M+26.8%
2021$24.55M+192.5%
2020$8.39M-